AURA Key Statistics, Chart & Performance
The current stock price of AURA is 5.88 USD. In the past month the price decreased by -3.76%. In the past year, price decreased by -29.41%.
AURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About AURA
Company Profile
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Company Info
AURA BIOSCIENCES INC
80 Guest Street
Boston MASSACHUSETTS US
CEO: Elisabet de los Pinos
Employees: 108
Phone: 16175008864
AURA BIOSCIENCES INC / AURA FAQ
Can you describe the business of AURA BIOSCIENCES INC?
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
What is the stock price of AURA BIOSCIENCES INC today?
The current stock price of AURA is 5.88 USD. The price decreased by -2.65% in the last trading session.
What is the dividend status of AURA BIOSCIENCES INC?
AURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AURA stock?
AURA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the ownership details for AURA stock?
You can find the ownership structure of AURA BIOSCIENCES INC (AURA) on the Ownership tab.
What is the outstanding short interest for AURA BIOSCIENCES INC?
The outstanding short interest for AURA BIOSCIENCES INC (AURA) is 5.65% of its float.
AURA Technical Analysis
AURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AURA. While AURA has a great health rating, there are worries on its profitability.
AURA Financial Highlights
Over the last trailing twelve months AURA reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS decreased by -10.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.03% | ||
| ROE | -67.96% | ||
| Debt/Equity | 0 |
AURA Forecast & Estimates
12 analysts have analysed AURA and the average price target is 18.87 USD. This implies a price increase of 220.92% is expected in the next year compared to the current price of 5.88.